Comprehensive Money Management Services LLC Reduces Position in Global X Genomics & Biotechnology ETF $GNOM

Comprehensive Money Management Services LLC decreased its position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 74.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,241 shares of the company’s stock after selling 15,264 shares during the period. Comprehensive Money Management Services LLC owned 0.43% of Global X Genomics & Biotechnology ETF worth $204,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GNOM. Flow Traders U.S. LLC grew its position in shares of Global X Genomics & Biotechnology ETF by 52.4% during the second quarter. Flow Traders U.S. LLC now owns 238,725 shares of the company’s stock worth $2,012,000 after acquiring an additional 82,063 shares during the last quarter. Insight Advisors LLC PA boosted its stake in Global X Genomics & Biotechnology ETF by 47.9% during the 2nd quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock worth $503,000 after purchasing an additional 19,319 shares during the period. Sei Investments Co. grew its position in Global X Genomics & Biotechnology ETF by 110.4% during the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after purchasing an additional 12,105 shares during the last quarter. Creative Financial Designs Inc. ADV increased its stake in Global X Genomics & Biotechnology ETF by 86.7% in the second quarter. Creative Financial Designs Inc. ADV now owns 22,301 shares of the company’s stock valued at $188,000 after purchasing an additional 10,358 shares during the period. Finally, Jane Street Group LLC raised its holdings in shares of Global X Genomics & Biotechnology ETF by 7.7% in the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after buying an additional 10,308 shares during the last quarter. Hedge funds and other institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of GNOM opened at $47.36 on Friday. Global X Genomics & Biotechnology ETF has a fifty-two week low of $27.20 and a fifty-two week high of $48.92. The firm has a 50-day simple moving average of $45.60 and a 200-day simple moving average of $40.40. The company has a market capitalization of $53.51 million, a price-to-earnings ratio of -20.24 and a beta of 1.22.

Global X Genomics & Biotechnology ETF Announces Dividend

The business also recently announced a dividend, which was paid on Wednesday, January 7th. Shareholders of record on Tuesday, December 30th were paid a $0.5912 dividend. This represents a dividend yield of 259.0%. The ex-dividend date was Tuesday, December 30th. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is -26.50%.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.